Smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy: a systematic review and meta-analysis

被引：9
作者：
Nie, Run-Cong [1 ]
Duan, Shu-Qiang YuanJin-Ling [1 ,3 ]
Liang, Yao [1 ]
Chen, Xiao-Jiang [1 ]
Chen, Yong-Ming [1 ]
Luo, Tian-Qi [1 ]
Chen, Guo-Ming [1 ]
Wang, Yun [2 ]
Li, Yuan-Fang [1 ]
机构：
[1] Sun Yat Sen Univ, Canc Ctr, State Key Lab Oncol South China, Dept Gastr Surg,Collaborat Innovat Ctr Canc Med, Guangzhou, Peoples R China
[2] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Dept Hematol Oncol,Canc Ctr, Guangzhou, Peoples R China
[3] Sun Yat Sen Univ, State Key Lab Oncol South China, Collaborat Innovat Ctr Canc Med, Canc Ctr, Guangzhou 510060, Peoples R China
来源：
IMMUNOTHERAPY | 2020年 / 12卷 / 18期
关键词：
efficacy; immunotherapy; overall survival; PD-1; PD-L1; smoking; OPEN-LABEL; CANCER-IMMUNOTHERAPY; CHOICE CHEMOTHERAPY; SOLID TUMORS; NIVOLUMAB; PEMBROLIZUMAB; DOCETAXEL; BLOCKADE; ATEZOLIZUMAB; MULTICENTER;
D O I：
10.2217/imt-2020-0007
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Aim:This study aimed to evaluate the relationship between smoking status and efficacy of PD-1/PD-L1 inhibitors compared with conventional agents.Materials & methods:We reviewed Phase II/III trials of PD-1/PD-L1 inhibitors that reported hazard ratio (HR) in current/former and never smoking patients.Results: 15 qualifying trials comprising 9073 patients were eligible in this study. Compared with conventional agents, PD-1/PD-L1 inhibitors correlated with prolonged progression-free survival (HR: 0.73; 0.58-0.92) and overall survival (HR: 0.75; 0.71-0.80) in current/former smoker patients but not in never-smoker patients (HR: 1.15 and 0.86 for progression-free survival and overall survival, respectively; both p > 0.05) irrespective of cancer type, target of experimental agents and treatment strategy.Conclusion:There exit smoking status-based efficacy difference in anti-PD-1/PD-L1 immunotherapy.
引用
收藏
页码：1313 / 1324
页数：12
相关论文
共 50 条
  • [11] New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
    Eisenhauer, E. A.
    Therasse, P.
    Bogaerts, J.
    Schwartz, L. H.
    Sargent, D.
    Ford, R.
    Dancey, J.
    Arbuck, S.
    Gwyther, S.
    Mooney, M.
    Rubinstein, L.
    Shankar, L.
    Dodd, L.
    Kaplan, R.
    Lacombe, D.
    Verweij, J.
    [J]. EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) : 228 - 247
  • [12] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [13] Ga W., The Newcastle-Ottawa Scale (NOS) for Assessing the Quality of Nonrandomised Studies in Meta-Analyses
  • [14] Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
    Gandhi, L.
    Rodriguez-Abreu, D.
    Gadgeel, S.
    Esteban, E.
    Felip, E.
    De Angelis, F.
    Domine, M.
    Clingan, P.
    Hochmair, M. J.
    Powell, S. F.
    Cheng, S. Y. -S.
    Bischoff, H. G.
    Peled, N.
    Grossi, F.
    Jennens, R. R.
    Reck, M.
    Hui, R.
    Garon, E. B.
    Boyer, M.
    Rubio-Viqueira, B.
    Novello, S.
    Kurata, T.
    Gray, J. E.
    Vida, J.
    Wei, Z.
    Yang, J.
    Raftopoulos, H.
    Pietanza, M. C.
    Garassino, M. C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) : 2078 - 2092
  • [15] Tobacco carcinogens, their biomarkers and tobacco-induced cancer
    Hecht, SS
    [J]. NATURE REVIEWS CANCER, 2003, 3 (10) : 733 - 744
  • [16] Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
    Hellmann, M. D.
    Paz-Ares, L.
    Bernabe Caro, R.
    Zurawski, B.
    Kim, S. -W.
    Carcereny Costa, E.
    Park, K.
    Alexandru, A.
    Lupinacci, L.
    de la Mora Jimenez, E.
    Sakai, H.
    Albert, I.
    Vergnenegre, A.
    Peters, S.
    Syrigos, K.
    Barlesi, F.
    Reck, M.
    Borghaei, H.
    Brahmer, J. R.
    O'Byrne, K. J.
    Geese, W. J.
    Bhagavatheeswaran, P.
    Rabindran, S. K.
    Kasinathan, R. S.
    Nathan, F. E.
    Ramalingam, S. S.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (21) : 2020 - 2031
  • [17] The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
    Higgins, Julian P. T.
    Altman, Douglas G.
    Gotzsche, Peter C.
    Jueni, Peter
    Moher, David
    Oxman, Andrew D.
    Savovic, Jelena
    Schulz, Kenneth F.
    Weeks, Laura
    Sterne, Jonathan A. C.
    [J]. BMJ-BRITISH MEDICAL JOURNAL, 2011, 343
  • [18] First-Line Atezolizumab plus Chemotherapy in Extensive-Stage Small-Cell Lung Cancer
    Horn, L.
    Mansfield, A. S.
    Szczesna, A.
    Havel, L.
    Krzakowski, M.
    Hochmair, M. J.
    Huemer, F.
    Losonczy, G.
    Johnson, M. L.
    Nishio, M.
    Reck, M.
    Mok, T.
    Lam, S.
    Shames, D. S.
    Liu, J.
    Ding, B.
    Lopez-Chavez, A.
    Kabbinavar, F.
    Lin, W.
    Sandler, A.
    Liu, S. V.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 379 (23) : 2220 - 2229
  • [19] Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
    Hugo, Willy
    Zaretsky, Jesse M.
    Sun, Lu
    Song, Chunying
    Moreno, Blanca Homet
    Hu-Lieskovan, Siwen
    Berent-Maoz, Beata
    Pang, Jia
    Chmielowski, Bartosz
    Cherry, Grace
    Seja, Elizabeth
    Lomeli, Shirley
    Kong, Xiangju
    Kelley, Mark C.
    Sosman, Jeffrey A.
    Johnson, Douglas B.
    Ribas, Antoni
    Lo, Roger S.
    [J]. CELL, 2016, 165 (01) : 35 - 44
  • [20] Nivolumab versus chemotherapy in patients with advanced oesophageal squamous cell carcinoma refractory or intolerant to previous chemotherapy (ATTRACTION-3): a multicentre, randomised, open-label, phase 3 trial
    Kato, Ken
    Cho, Byoung Chul
    Takahashi, Masanobu
    Okada, Morihito
    Lin, Chen-Yuan
    Chin, Keisho
    Kadowaki, Shigenori
    Ahn, Myung-Ju
    Hamamoto, Yasuo
    Doki, Yuichiro
    Yen, Chueh-Chuan
    Kubota, Yutaro
    Kim, Sung-Bae
    Hsu, Chih-Hung
    Holtved, Eva
    Xynos, Ioannis
    Kodani, Mamoru
    Kitagawa, Yuko
    [J]. LANCET ONCOLOGY, 2019, 20 (11) : 1506 - 1517
12345